文献速递免疫规划

Ad26.RSV.preF/RSV preF蛋白疫苗不同剂量在60岁及以上成人中的免疫原性与安全性:一项随机、双盲、安慰剂对照的2a期研究

Immunogenicity and safety of different dose levels of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 years and older: A randomized, double-blind, placebo-controlled, phase 2a study.
PubMed 文献 · Vaccine · 2024-09-13

这项随机、双盲、安慰剂对照2a期研究纳入454名60岁及以上健康成人,评估不同剂量Ad26.RSV.preF联合固定剂量RSV preF蛋白(150 μg)疫苗的免疫原性与安全性。结果显示各Ad26.RSV.preF剂量(3.7×10^9至1.6×10^11病毒颗粒)与1.0×10^11 vp相比免疫应答无实质差异,所有剂量耐受良好,未发现安全性问题。

要点

  • 各Ad26.RSV.preF剂量与1.0×10^11 vp相比,所有接种后时间点免疫应答无实质差异。
  • 3.7×10^9至1.6×10^11 vp所有剂量均耐受良好,未发现安全性问题。
  • 结果可用于优化Ad26.RSV.preF成品的放行与稳定性标准。

核心结论

  • 这项剂量探索研究的结果可用于指导Ad26.RSV.preF成品放行与稳定性标准的完善。

研究设计与样本

  • 随机、双盲、安慰剂对照的2a期研究,纳入60岁及以上健康或病情稳定成人,随机分配至3个队列之一接受安慰剂或Ad26.RSV.preF/RSV preF蛋白疫苗。
  • 疫苗含不同剂量Ad26.RSV.preF与固定剂量RSV preF蛋白150 μg;队列1(4个降剂量组)Ad26.RSV.preF剂量范围为3.7×10^9至1.0×10^11病毒颗粒(vp),队列2和3(各2个升剂量组)剂量范围为1.0至1.6×10^11 vp。
  • 共454名参与者入组并接种1剂研究疫苗或安慰剂(队列1 n=226;队列2 n=124;队列3 n=104)。
  • 队列1主要终点为免疫原性(RSV preF蛋白抗体滴度),队列2和3主要终点为安全性(征集性局部和全身不良事件及非征集性不良事件)。
  • 免疫原性分析于接种当天及接种后14天、3个月和6个月进行;安全性监测从接种至研究结束。

主要发现

  • 与Ad26.RSV.preF 1.0×10^11 vp相比,较低或较高Ad26.RSV.preF剂量在所有接种后时间点所测免疫应答均无实质差异。
  • 3.7×10^9 vp至1.6×10^11 vp之间所有Ad26.RSV.preF剂量均耐受良好,未发现安全性问题。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Respiratory syncytial virus (RSV) can cause severe illness in older adults. A combination vaccine containing Ad26.RSV.preF and purified recombinant RSV preF protein has previously demonstrated efficacy and tolerability in older adults. We report results of a dose-ranging study to determine immunogenicity and safety of different doses of the Ad26.RSV.preF component in the combined Ad26.RSV.preF/RSV preF protein vaccine to support Ad26.RSV.preF drug product release and stability specifications. METHODS: In this randomized, double-blind, placebo-controlled, phase 2a study, adults aged ≥60 years in good or stable health were randomly assigned within 1 of 3 cohorts to receive either placebo or Ad26.RSV.preF/RSV preF protein, composed of different doses of Ad26.RSV.preF with a fixed dose of RSV preF protein (150 μg). Ad26.RSV.preF doses in Cohort 1 (4 dose-down groups) ranged from 3.7 × 109 to 1.0 × 1011 viral particles (vp). Doses in Cohorts 2 and 3 (2 dose-up groups, each) ranged from 1.0 to 1.6 × 1011 vp. Primary endpoints were immunogenicity (RSV preF protein antibody titers) for Cohort 1 and safety (solicited local and systemic adverse events [AEs] and unsolicited AEs) for Cohorts 2 and 3. Immunogenicity analyses (RSV preF protein antibody titers, RSV A2 neutralizing antibodies, and RSV-F-specific interferon-γ enzyme-linked immunosorbent spot) were performed on the day of vaccination and 14 days, 3 months, and 6 months postvaccination. Safety was monitored from vaccination until study end. RESULTS: Overall, 454 participants were enrolled and received 1 dose of study vaccine or placebo (Cohort 1, n = 226; Cohort 2, n = 124; Cohort 3, n = 104). No substantial differences in measured immune responses were observed between lower or higher Ad26.RSV.preF doses compared with Ad26.RSV.preF 1.0 × 1011 vp across all postvaccination time points. All Ad26.RSV.preF doses between 3.7 × 109 vp and 1.6 × 1011 vp were well tolerated, with no safety issues identified. CONCLUSIONS: Results of this dose-ranging study may be used to inform the refinement of Ad26.RSV.preF drug product release and stability specifications. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04453202.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. van Heesbeen R, Bastian AR, Omoruyi E, et al. Immunogenicity and safety of different dose levels of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 years and older: A randomized, double-blind, placebo-controlled, phase 2a study. Vaccine. 2024. PMID: 39276619. doi:10.1016/j.vaccine.2024.126273

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。